Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 595 of 5804
-
New antibody drug aims to stop NMOSD attacks in AQP4-positive patients
Disease control OngoingThis is a phase II/III multicenter, randomized, double-blind, placebo-controlled study, to investigate the efficacy and safety of BAT4406F injection in patients with neuromyelitis optica lineage disease (NMOSD) who are positive for aquaporin 4 antibody (AQP4-IgG) .
Phase: PHASE2 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New immunotherapy aims to fight advanced liver cancer
Disease control TerminatedThis is a randomized, controlled multi-site, multi-national clinical trial conducted in Thailand and Malaysia for Asian adults (males or females), 18 years of age and older presenting with advanced HCC (BCLC stage C) including subjects with macrovascular involvement and/or extrah…
Phase: PHASE2, PHASE3 • Sponsor: Mirror Biologics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for Crohn's patients: drug may prevent bowel surgery
Disease control CompletedMany patients with Crohn's disease develop fibrotic narrowing (strictures) in their bowel, causing obstructive symptoms such as abdominal pain, cramping, or vomiting after meals. Because of these symptoms, patients often require bowel resection surgery. The objective of this clin…
Phase: PHASE2 • Sponsor: Agomab Spain S.L.U. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New vaccine aims to train immune system against HPV throat cancer
Disease control Recruiting nowThis study is a multicentric double-blind placebo-controlled dose escalation trial of a CD40HVac vaccine (humanized anti-CD40 mAb fused to HPV16 E6/E7 oncoproteins) adjuvanted with poly-ICLC (Hiltonol) in patients with HPV16 oropharyngeal carcinoma with no evidence of residual or…
Phase: PHASE1, PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New blood test aims to catch colon cancer sooner
Diagnosis Recruiting nowThis study is designed to prospectively collect blood samples and clinical data from patients that have been newly diagnosed with colorectal cancer and scheduled for resection surgery but are pre cancer treatment, subjects who are NOT scheduled for surgery but have histological c…
Sponsor: Universal Diagnostics • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
Tailored treatment shows promise for slowing early dementia
Disease control CompletedThe goal of this clinical trial is to compare a precision medicine approach to the standard-of-care for people with mild cognitive impairment or early-stage dementia. Precision medicine approach starts with the completion of many tests and then the study doctor uses the test resu…
Phase: PHASE3 • Sponsor: Alzheimer's Prevention and Reversal Project, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New pill shows promise for tough lung cancer mutation
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.
Phase: PHASE2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New TB vaccines enter human trials – could they beat the world’s deadliest infection?
⭐️ VACCINE ⭐️ OngoingThis is a two-part randomized, placebo-controlled, observer-blind, safety and dose-finding Phase Ib/IIa study. This study will evaluate up to four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to select a safe and tolerable dose in a three-dose schedu…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:03 UTC
-
Patch aims to cut rotator cuff Re-Tear rate after surgery
Disease control Recruiting nowRotator cuff (RC) injuries are particularly prevalent, difficult to repair, and attachment between the bone and tendon is notoriously difficult to achieve. The most common method and current standard of care (SOC) for reattaching connective tissues (e.g., ligaments, tendons) to b…
Phase: PHASE4 • Sponsor: Brooke Army Medical Center • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New RSV vaccine shows promise for transplant patients
⭐️ VACCINE ⭐️ CompletedThe purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of the RSVPreF3 OA investigational vaccine in an immunocompromised (lung and renal transplant recipients) population and assess whether a second dose of the vaccine increases the immune respon…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo aims to tackle Chemotherapy-Resistant colorectal cancer in the abdomen
Disease control OngoingThis is a two-center open-label non-randomized proof of principle study consisting of a dose-finding part (phase I) and phase II study with Simon two-stage design investigating the anti-tumor activity of the combination of capecitabine and galunisertib in patients with colorectal…
Phase: PHASE1, PHASE2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat GI tumors
Disease control Recruiting nowThis study is to evaluate the efficacy of the LM-302 Combination With Other Therapies in patients with CLDN18.2-positive Advanced Digestive Tract Tumor.
Phase: PHASE2 • Sponsor: LaNova Medicines Zhejiang Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:47 UTC
-
Could two HPV shots be enough for women with HIV?
⭐️ VACCINE ⭐️ Recruiting nowThere are very little data on human papillomavirus (HPV) vaccination among the 18 million women living with HIV (WLWH) globally, who constitute a population most vulnerable to HPV and the resultant cervical cancer. Particularly, there are no data to date on reduced-dose schedules…
Phase: PHASE4 • Sponsor: University of British Columbia • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:02 UTC
-
New shot shows promise against fatty liver disease
Disease control CompletedPurpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
Phase: PHASE2 • Sponsor: Altimmune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Promising drug targets rare childhood cancers in new trial
Disease control Recruiting nowThe purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New combo therapy aims to knock out high-risk prostate cancer
Disease control Recruiting nowThis trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized prostate cancer.
Phase: PHASE2 • Sponsor: Zin W Myint • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New RSV shot shows promise for vulnerable babies
Disease control CompletedThe purpose of this study is to measure the safety, PK, occurrence of ADA to nirsevimab, and anti-RSV neutralizing Ab in Japanese children with certain health conditions or pre-term infants aged ≤12 months. Study details include * The study duration is approximately 21 months w…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Personalized drug attack on salivary gland tumors shows promise
Disease control OngoingThis is a single-center, open-label, phase 2 study to evaluate the efficacy and safety of target therapy for patients with relapsed/metastastic salivary gland carcinoma based on molecular typing.
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Moderna tests mRNA shots to stop lyme disease
⭐️ VACCINE ⭐️ CompletedThe purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Mar 23, 2026 13:22 UTC
-
Can an antiviral cure long COVID? new trial tests paxlovid
Disease control CompletedThis study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, mul…
Phase: PHASE2 • Sponsor: Kanecia Obie Zimmerman • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC